Lancet Regional Health-Europe最新文献

{"title":"A global commitment to addressing chronic liver disease","authors":"Vanessa Garcia-Larsen , Kremlin Wickramasinghe , Anselm J. Hennis","doi":"10.1016/j.lanepe.2026.101723","DOIUrl":"10.1016/j.lanepe.2026.101723","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101723"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Closing the Implementation Gap: New Models of Care to End Chronic Liver Disease","authors":"Fernando Bril , Fasiha Kanwal , Kenneth Cusi","doi":"10.1016/j.lanepe.2026.101739","DOIUrl":"10.1016/j.lanepe.2026.101739","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101739"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Medicines Agency approvals of new medicines in March and April 2026","authors":"Bruno Sepodes , Juan Garcia Burgos , Steffen Thirstrup","doi":"10.1016/j.lanepe.2026.101714","DOIUrl":"10.1016/j.lanepe.2026.101714","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101714"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Stroke Organisation Conference (ESOC) 2026","authors":"Stephanie Becker","doi":"10.1016/j.lanepe.2026.101726","DOIUrl":"10.1016/j.lanepe.2026.101726","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101726"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe","authors":"Camila A. Picchio ,&nbsp;Aina Nicolàs ,&nbsp;Erika Duffell ,&nbsp;Elisa Martró ,&nbsp;Peter Vickerman ,&nbsp;Sandra Dudareva ,&nbsp;Sabela Lens ,&nbsp;Axelle Vanderlinden ,&nbsp;Joaquin Cabezas ,&nbsp;Xavier Forns ,&nbsp;Upkar S. Gill ,&nbsp;Devin Razavi-Shearer ,&nbsp;Alessio Aghemo ,&nbsp;Rachel Halford ,&nbsp;Thomas Vanwolleghem ,&nbsp;Philippa C. Matthews","doi":"10.1016/j.lanepe.2026.101712","DOIUrl":"10.1016/j.lanepe.2026.101712","url":null,"abstract":"<div><div>Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain public health threats in the WHO European region, where an estimated 29 million people live with chronic infection and viral hepatitis-related deaths now surpass those from HIV/AIDS and tuberculosis combined. Although effective prevention tools and antiviral treatments reduce the risk of complications, overall mortality has not declined. This Series paper reviews models of care (MoC) implemented between 2015 and 2025, drawing on scientific literature and policy documents to assess regional progress. Simplified testing and treatment, childhood and targeted adult HBV vaccination, harm-reduction programmes, and prison-based interventions have advanced elimination efforts. Pragmatic approaches, including point-of-care testing, decentralised services, and integrated models tailored to key populations demonstrate clear benefits. However, major challenges persist: large undiagnosed populations, regional disparities, inadequate healthcare worker knowledge, and inequities affect at-risk groups. Achieving elimination by 2030 will require accelerated case-finding, broader access to simplified treatment, stronger risk-tailored and vaccination strategies, improved data systems, and renewed commitment.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101712"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe","authors":"Elisa Pose ,&nbsp;Luis Antonio Díaz ,&nbsp;Richard Parker ,&nbsp;Mads Israelsen ,&nbsp;Thomas Marjot ,&nbsp;Ewan Forrest ,&nbsp;Ashwin Dhanda ,&nbsp;Catherine Paradis ,&nbsp;Juan Pablo Arab ,&nbsp;Aleksander Krag ,&nbsp;Ramón Bataller ,&nbsp;Frank Murray ,&nbsp;Jeffrey V. Lazarus ,&nbsp;Patrizia Carrieri ,&nbsp;Paul N. Brennan","doi":"10.1016/j.lanepe.2026.101707","DOIUrl":"10.1016/j.lanepe.2026.101707","url":null,"abstract":"<div><div>Alcohol-related liver disease (ALD) remains a leading cause of preventable morbidity and mortality in Europe. Despite robust evidence that alcohol-related population-level policies delay use initiation and reduce associated harms, their implementation in Europe has been inconsistent and frequently undermined by alcohol industry interference, fragmented governance, and policy inertia. The burden of ALD as well as combined metabolic dysfunction and alcohol-associated liver disease (MetALD) has grown steadily, driven by increased alcohol intake, widespread metabolic risk factors, delayed diagnosis, and poor integration between primary care, substance use services, endocrinology, and hepatology. In this Series paper, we combine epidemiology, policy evaluations, and clinical evidence to examine these findings through the lenses of policy, system preparedness, education, and stigma. We highlight screening strategies for alcohol use and liver disease and describe models of multidisciplinary and digital care. Finally, we outline priorities for policy reform, stigma reduction, youth-focused prevention, and research on biomarkers, pharmacotherapies, and digital/artificial intelligence tools.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"65 ","pages":"Article 101707"},"PeriodicalIF":13.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of bispecific and multispecific antibodies in cancer therapy","authors":"Elisa Fontana ,&nbsp;Rafael Grochot ,&nbsp;Nuria Kotecki ,&nbsp;Bernard Doger ,&nbsp;Simon Nannini ,&nbsp;María de Miguel","doi":"10.1016/j.lanepe.2026.101599","DOIUrl":"10.1016/j.lanepe.2026.101599","url":null,"abstract":"<div><div>Antibody-based cancer therapy has rapidly evolved from monoclonal antibodies to bispecific and multispecific constructs that combine distinct binding specificities and mechanisms. These agents are seeing increasing clinical adoption, with European Medicines Agency approvals in haematological malignancies and selected solid tumours such as uveal melanoma and EGFR-mutant non-small-cell lung cancer. However, they are often still discussed as a single drug class, which does not capture the complexity of current formats and mechanisms, ranging from IgG-like to fragment-based architectures and from immune-cell redirection to dual immune modulation or oncogenic pathway blockade. This Series paper provides an integrated classification framework based on mechanism and format, relating key design features to pharmacology, efficacy, and safety. It synthesizes clinical evidence and ongoing development, discusses practical strategies to mitigate hallmark toxicities, and reviews emerging resistance mechanisms and rational combination approaches. It also outlines next generation directions, including higher order multispecific constructs, conditionally active antibodies, and payload conjugated multispecific formats. To consolidate these agents as an established therapeutic modality in oncology, priority should be given to rigorous understanding of mechanisms of action and toxicity, alongside rational optimisation of construct design and dosing, supported by robust prospective translational programmes.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101599"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjunctive betamethasone treatment of hypoxaemic adults hospitalised with Mycoplasma pneumoniae community-acquired pneumonia: an open-label, multicentre, randomised, controlled trial","authors":"Karl Hagman ,&nbsp;Magnus Hedenstierna ,&nbsp;Elina Andersson Norlén ,&nbsp;Karin Biasoletto ,&nbsp;Maria Eklund Josephson ,&nbsp;Carl-Johan Fraenkel ,&nbsp;Elin Hedman ,&nbsp;Johan Ljungberg ,&nbsp;Oskar Ljungquist ,&nbsp;Viktor Månsson ,&nbsp;David Nygren ,&nbsp;Milena de Oliveira e Costa ,&nbsp;Cecilia Rydén ,&nbsp;Jørgen Skov Jensen ,&nbsp;Göran Stenlund ,&nbsp;Jonas Tverring ,&nbsp;Lisa Wasserstrom ,&nbsp;Anna C. Nilsson ,&nbsp;Johan Ursing","doi":"10.1016/j.lanepe.2026.101610","DOIUrl":"10.1016/j.lanepe.2026.101610","url":null,"abstract":"<div><h3>Background</h3><div>Adjunctive corticosteroid therapy appears to be beneficial for adults with severe community-acquired pneumonia (CAP), but data on <em>Mycoplasma pneumoniae</em> CAP are limited. This study aimed to evaluate if adjunctive betamethasone reduced time to resolution of hypoxaemia in adults hospitalised with <em>M. pneumoniae</em> CAP.</div></div><div><h3>Methods</h3><div>An open-label, multicentre, randomised, controlled trial was conducted at eight Swedish hospitals. Adults admitted with <em>M. pneumoniae</em> CAP and hypoxaemia (SpO₂ &lt;93% and respiratory rate &gt;20 breaths/min) were eligible. Exclusion criteria included asthma and diabetes mellitus. Participants were randomised (1:1) to either standard care without corticosteroids or adjunctive oral betamethasone (3 mg daily on days 1–2, and 2 mg daily on days 3–5). Antibiotic treatment was standardised to 200 mg doxycycline once daily for 10 days. The primary outcome was time to resolution of hypoxaemia in an intention-to-treat analysis. Safety was assessed in participants receiving at least one betamethasone dose. The study was registered with the EU Clinical Trials Register (EudraCT 2016-002585-32) and is completed.</div></div><div><h3>Findings</h3><div>Between March 1, 2018, and November 14, 2024, 70 participants were enrolled: 36 in the betamethasone group and 34 in the control group. The median age was 42 years (IQR 28–49) including 40 (57%) male and 30 (43%) female participants. All participants achieved resolution of hypoxaemia except two who withdrew consent. Time to resolution of hypoxaemia was shorter in the betamethasone group (HR 1.82 [95% CI 1.10–3.02], p = 0.020) compared to the standard of care group, with an estimated median of 2.3 (95% CI 1.8–2.7) and 3.6 (95% CI 1.9–5.3) days, respectively. Adverse events were similar between study groups. Severe adverse events were rare, and none were attributed to betamethasone treatment.</div></div><div><h3>Interpretation</h3><div>Adjunctive betamethasone was well tolerated and significantly shortened the duration of hypoxaemia in adults hospitalised with <em>M. pneumoniae</em> CAP in this open-label trial.</div></div><div><h3>Funding</h3><div><span>The Swedish Society of Medicine</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101610"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing oncology innovation under persistent constraints","authors":"Dario Trapani ,&nbsp;Giuseppe Curigliano","doi":"10.1016/j.lanepe.2026.101694","DOIUrl":"10.1016/j.lanepe.2026.101694","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101694"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline","authors":"Massimo Filippi ,&nbsp;Giordano Cecchetti ,&nbsp;Edoardo G. Spinelli ,&nbsp;Alma Ghirelli ,&nbsp;Giulia Rugarli ,&nbsp;Stefano Pisano ,&nbsp;Elisa Canu ,&nbsp;Federica Agosta","doi":"10.1016/j.lanepe.2026.101609","DOIUrl":"10.1016/j.lanepe.2026.101609","url":null,"abstract":"<div><div>The introduction of anti-amyloid monoclonal antibodies marks a major shift in Alzheimer's disease (AD) care, moving treatment toward biological modification and reshaping diagnostic and organizational models. At the Center for Alzheimer's and Related Diseases (CARD), IRCCS San Raffaele Hospital (Milan, Italy), among the first European tertiary centers to initiate both lecanemab and donanemab, we developed a structured fast-track pathway to support timely and safe access to therapy. Our early real-world experience highlights three critical domains. First, patient selection requires integration of cognitive, functional, and biological data, moving beyond rigid global score thresholds. Second, safety monitoring must balance ARIA risk with real-world feasibility through risk-adapted MRI surveillance. Third, effective implementation depends on transparent communication and continuous shared decision-making, particularly when benefit is uncertain or safety events occur. These elements underscore that the impact of disease-modifying therapies will depend not only on pharmacology, but on coordinated care models supported by real-world registries.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101609"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146162013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}